Lophius Biosciences seal further round of finance
Lophius Biosciences GmbH, a biotechnology company founded from the Regensburg University Clinic, is developing innovative products for the diagnosis of transplantation, autoimmune and infectious diseases. The company does this by using innovative T cell-based test systems for diagnosis and possible modulation of treatment. The so-called T cell-based technology platform was so convincing to the current financial investors S-Refit (a regional venture capital company), the Germany High-Tech founder´s fund (HTGF) and Bayernkapital (Venture capital company in Bavaria), that they increased their investment to round 1.4 million €. The funding is to be used to introduce a novel testing system at the start of 2012 in the field of transplantation, for the further development of a diagnostic test for the differential diagnosis of tuberculosis as well as the new development of a novel blood-based multiple sclerosis test. The company, which currently is still located in BioPark I, is to move to its new premises in September to the new BioPark III building growing strongly to 600 m2. The new finances now allow further development with a highly effective team of a small, highly innovative and fully integrated diagnostic company with huge marketability.
For more information see: